Blair William & Co. IL Decreases Stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

Posted by Defense World Staff on Jun 3rd, 2023

Blair William & Co. IL lowered its position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Get Rating) by 72.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 45,881 shares of the medical research company’s stock after selling 123,662 shares during the quarter. Blair William & Co. IL owned approximately 0.06% of Accelerate Diagnostics worth $32,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Griffin Asset Management Inc. increased its holdings in shares of Accelerate Diagnostics by 17.3% in the 4th quarter. Griffin Asset Management Inc. now owns 8,569,742 shares of the medical research company’s stock valued at $6,050,000 after acquiring an additional 1,266,786 shares during the period. State Street Corp increased its holdings in shares of Accelerate Diagnostics by 30.3% in the 3rd quarter. State Street Corp now owns 320,984 shares of the medical research company’s stock valued at $488,000 after acquiring an additional 74,700 shares during the period. Jacobs Levy Equity Management Inc. acquired a new position in shares of Accelerate Diagnostics in the 3rd quarter valued at $163,000. Two Sigma Investments LP acquired a new position in shares of Accelerate Diagnostics in the 3rd quarter valued at $329,000. Finally, Vanguard Group Inc. increased its holdings in shares of Accelerate Diagnostics by 22.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,825,643 shares of the medical research company’s stock valued at $4,295,000 after acquiring an additional 520,656 shares during the period. Hedge funds and other institutional investors own 33.14% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of Accelerate Diagnostics in a report on Thursday, May 18th. They issued a “sell” rating on the stock.

Insider Buying and Selling

In other Accelerate Diagnostics news, CEO Jack Phillips sold 155,635 shares of the company’s stock in a transaction dated Wednesday, March 8th. The shares were sold at an average price of $0.47, for a total value of $73,148.45. Following the transaction, the chief executive officer now directly owns 463,823 shares in the company, valued at approximately $217,996.81. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Accelerate Diagnostics news, CEO Jack Phillips sold 155,635 shares of the company’s stock in a transaction dated Wednesday, March 8th. The shares were sold at an average price of $0.47, for a total value of $73,148.45. Following the transaction, the chief executive officer now directly owns 463,823 shares in the company, valued at approximately $217,996.81. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Steven Reichling sold 62,778 shares of the company’s stock in a transaction dated Wednesday, March 8th. The shares were sold at an average price of $0.47, for a total transaction of $29,505.66. Following the completion of the transaction, the chief financial officer now owns 137,640 shares in the company, valued at $64,690.80. The disclosure for this sale can be found here. Insiders have sold 251,805 shares of company stock worth $123,024 in the last three months. Corporate insiders own 42.20% of the company’s stock.

Accelerate Diagnostics Stock Performance

Shares of NASDAQ AXDX opened at $0.75 on Friday. The firm has a market capitalization of $74.87 million, a P/E ratio of -1.04 and a beta of 1.19. Accelerate Diagnostics, Inc. has a one year low of $0.45 and a one year high of $3.74. The company’s fifty day moving average is $0.73 and its two-hundred day moving average is $0.69.

Accelerate Diagnostics (NASDAQ:AXDX – Get Rating) last issued its earnings results on Wednesday, March 29th. The medical research company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.02. The company had revenue of $2.97 million for the quarter, compared to analysts’ expectations of $3.00 million. On average, sell-side analysts forecast that Accelerate Diagnostics, Inc. will post -0.59 earnings per share for the current fiscal year.

Accelerate Diagnostics Company Profile

(Get Rating)

Accelerate Diagnostics, Inc is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens.

Institutional Ownership by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.